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Abstract:
Introduction: The primary focus on vitamin D therapy 
was to treat metabolic bone disease. Over the past decade, 
however, researchers have demonstrated that vitamin D 
may have a role in other disease processes, particularly 
cardiovascular diseases (CVDs).
Review: Serum 25-hydroxyvitamin D (25(OH)D) 
deficiency is widespread, and is extremely common in 
kidney transplant recipients. In community surveys, lower 
levels of 25(OH)D were associated with significantly 
higher adjusted prevalence of cardiovascular risk factors 
and CVD. CVD patients have lower 25(OH)D levels than 
controls, which are associated with more severe disease 
and worse prognosis. 25(OH)D levels are inversely 
associated with insulin resistance and future risk of 
hyperglycemia in non-diabetic subjects. Low levels of 
25(OH)D were found to be independent predictors of 
death and end stage renal disease (ESRD) in chronic 
kidney disease (CKD) patients. Supplementation with 
vitamin D was found to lower parathyroid hormone and 
increase anti-inflammatory cytokines in congestive heart 
failure patient. It was found to improve flow mediated 
vasodilatation of the brachial artery in asymptomatic 
vitamin D deficient subjects and diabetic patients. Vitamin 
D supplementation was found to reduce proteinuria, 
mortality and progression to dialysis in CKD patients 
and to reduce cardiovascular mortality in hemodialysis 
patients. Vitamin D and calcium supplementation was 
also found to reduce cancer risk in community dwelling 
healthy postmenopausal women.
Conclusion: Low levels of vitamin D seem to have 
undesirable effects on health. Based on the results of 
recent research, the recommended lower value of serum 
25(OH)D is likely to be elevated.
Key Words: Vitamin D; Cardiovascular disease ; Chronic 
kidney disease 
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Introduction
The most important physiological source of vitamin D, 
the ''sunshine vitamin'', in humans is the production of 
vitamin D3 (cholecalciferol) in the skin. Vitamin D3 is 
produced in the skin by the photochemical conversion 
of its provitamin, 7-dehydrocholesterol. Both vitamin 
D3 and vitamin D2 (ergocalciferol) are present in small 
amounts in the diet. However, dietary vitamin D is often 
insufficient to protect against vitamin D deficiency in the 
absence of solar exposure. 
Both forms of vitamin D undergo hydroxylation, mainly 
in the liver, to 25-hydroxyvitamin D [25(OH)D]. This is 
the main circulating storage metabolite of vitamin D. A 
proportion of 25(OH)D is then converted in the kidney to 
the active metabolite 1,25 dihydroxvitamin D [1,25(OH)
D], or calcitriol. This step is under tight regulation, being 
enhanced by parathyroid hormone (PTH), hypocalcemia 
and hypophosphatemia, and suppressed by hypercalcemia, 
hyperphosphatemia and impaired renal function [1].
Besides its well known role in bone metabolism, vitamin 
D has documented associations with a number of health 
conditions. For the purpose of this review, we performed 
a Medline search for English publications back to 1980, 
using the words “vitamin D”, “human studies”, and 
“Cardiovascular Disease”. In this review, we will discuss 
the mechanism(s) of 25(OH)D actions, prevalence and 
causes of 25(OH)D deficiencies, clinical syndromes 
associated with 25(OH)D deficiencies and the therapeutic 
potential of 25(OH)D to promote cardiovascular health.
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Mechanism of 25(OH)D action
Clinical studies have demonstrated an association between 
vitamin D deficiency and a number of conditions, most 
prominent of which is cerebrovascular disease. This has 
encouraged researchers to look for possible mechanisms 
of action that may explain the anti-inflammatory and 
atherosclerotic properties of vitamin D (Tables 1 and 2).
Definition and prevalence of 25(OH)D deficiencies
Serum 25-hydroxyvitamin D (25(OH)D) concentration is 
accepted as the functional indicator of vitamin D status 
[18]. The normal range of 25(OH)D is 10-55 ng/ml for all 
gender and life stage groups. However, there is evidence, 
specially in the elderly, that in order for the PTH to be 
at the optimum level, a 25(OH)D level of 20 ng/ml or 
greater may be required [18]. Based on the results of 
recent research, the recommended lower value of serum 
25(OH)D is likely to be elevated. Table 3 demonstrates 
the serum 25(OH)D concentration levels corresponding 
to health status in humans. The daily requirement of 
vitamin D varies between 10 to 20 mcg/day (400-800 IU/
day) [18].  At the other extreme, large doses of vitamin 
D are not recommended. Excessive amounts of vitamin 
D cause vomiting, constipation, and weight loss. Human 
data on this specific topic are very limited. 
Vitamin D deficiency is widespread amongst children, 
adolescents, adults, and senior citizens. Its prevalence 
varies with ethnicity, nationality, and global location. 
Causes of 25(OH)D Deficiency
Deficiency in 25(OH)D can result from a number of 
reasons. The commonest reason is inadequate exposure 
to the sun accompanied by inadequate dietary intake or 
malabsorption [1].
Inadequate exposure to sunlight: Ultraviolet B rays 
are needed for the synthesis of vitamin D in the skin, the 
prime natural source of this vitamin. Insufficient exposure 
to sunlight causes deficiency in cutaneously synthesized 
vitamin D. Adults in nursing homes or health care 
institutions are at particularly high risk. Patients with large 
skin grafts also have a marked reduction in their ability 
to synthesize vitamin D in the skin. The optimal daily 
sunshine exposure an individual should get is subject to 
debate. It is recommended that an individual receives10 
to 15 minutes of sun exposure, 3 times a week during none 
peak sun hours. With age, the efficiency of processing 
vitamin D becomes less and vitamin D supplementation 
may be necessary. Darker skin individuals living in the 
northern hemisphere and individuals using sunscreen 
that reduce absorption of ultraviolet B rays are also likely 
to need vitamin D supplementation.
Inadequate intake: Minimal amounts of vitamin D exist 
in human breast milk. Therefore the American Academy 
of Pediatrics recommended that all children receive 400 
IU/day of vitamin D from their first few days of life 
through adolescence [19].
Vitamin D malabsorption syndrome: People who have 
undergone resection of the small intestine are at risk for 
this condition. Other diseases associated with vitamin D 
malabsorption include celiac sprue and cystic fibrosis.
Obesity: Individuals with obesity have reduced 
availability of vitamin D in their body fat. Lower levels 
of 25(OH)D were found in morbidly obese and obese 
women compared to non-obese women [20].
Medications: Some medications are associated 
with vitamin D deficiency. Drugs such as dilantin, 
phenobarbitals  and rifampin can induce hepatic p450 
enzymes and accelerate the catabolism of vitamin D.
Liver disease: Decreased synthesis of 25(OH)D occurs 
in patients with liver disease.
Renal diseases: In data from Third National Health 
and Nutrition Examination Survey, the adjusted odds 
for 25(OH)D deficiency were 32% higher in chronic 
kidney disease (CKD) patients [21]. Serum 25(OH)
D deficiency is also extremely common among kidney 
transplant recipients [22, 23], and even kidney transplant 
recipients with adequate renal function were found to 
have significantly lower 25(OH)D levels than age and 
gender-matched controls [24]. Courbebaisse et al [25] 
were able to demonstrate that treating kidney transplant 
recipients deficient in 25(OH)D with 100,000 units 
of cholecalciferol every 2 weeks for 2 months may be 
enough to significantly elevate serum levels of 25(OH)D 
to above 30 ng/ml and reduce PTH levels without neither 
consequent hypercalcemia nor increased urinary calcium 
excretion, which could adversely affect graft function. 
However, during the less intensive phase of the treatment, 
when cholecalciferol was given at the same dose every 
other month, serum levels of 25(OH)D decreased again, 
though they remained higher than in control untreated 
patients at 1 year after transplantation. The message to 
be drawn from this study is that we need to prescribe 
large doses of cholecalciferol for our patients after renal 
transplantation. In addition, we need similar bold studies 
on the correct dose of cholecalciferol or ergocalciferol to 
prescribe for our patients at the different stages of CKD. 
Deficiency in the metabolically active form of vitamin 
D, 1,25(OH)D, is common in patients with CKD. In 
the early stages of CKD, hyperphosphatemia induces 
fibroblast growth factor 23 (FGF-23), a phosphaturic 
hormone which down regulates 25(OH)D hydroxylase 
activity.  In CKD stages 4 and 5, the kidney is unable to 
produce adequate amounts of 1,25(OH)D [26]. 
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Table 1: In vitro studies exploring the possible mechanisms of action of vitamin D in preventing cardiovascular disease
Possible mechanisms of action of vitamin D in preventing cardiovascular disease
In cultured rabbit VSMCs, prostacyclin  synthesis was significantly increased in the presence of 1,25(OH)D and 1(OH)D. Treament • 
with 1,25(OH)D significantly induced the activity of cyclooxygenase without changing the activity of phospholipase A2 [2]. 
In cultured human HUVEC, calcitriol decreased the adhesion molecules expression, as well as LPS induced mRNA expressions of RAGE • 
and IL-6, and IL-6 and LPS induced IL-6 secrtion. Calcitriol also decreased the LPS induced KFkB-p65 DNA-binding activity [3]. 
In HMEC, pretreatment with 1,25(OH)D inhibited the enteric gram-negative bacterial LPS activation of transcription factor NFkB • 
and IL-6, IL-8 and RANTES release [4].
In cultured bovine VSMCs, 1,25(OH)D increased VSMC calcification and alkaline phosphatase activity in a dose-dependent • 
manner. 1,25(OH)D decreased secretion of PTHrP by bovine VSMCs in a dose-dependent manner and depressed its gene expres-
sion. 1,25(OH)D also increased the expression of the osteopontin gene, one of the bone matrix proteins in  bovineVSMCs, contrib-
uting to its stimulatory action on bovine VSMC calcification [5].
In activated human T lymphocytes, calcitriol markedly inhibited at the transcriptional level the production of IFN-gamma. Calcit-• 
riol down regulated both IL-2 and IFN-gamma production as well as TfR expression at the mRNA level [6].
In rat aortic VSMC, 1,25(OH)D induced a dose-dependent increase in rate of migration. This response required the activation of • 
PI3 kinase because it was completely abolished by the PI3 kinase inhibitors, LY294002 or wortmannin. The RNA polymerase 
inhibitor, 5,6-dichlorobenzimidazole riboside did not affect the 1,25(OH)D induced VSMC migration, suggesting that gene tran-
scription is not involved in this rapid response [7]. 
In rat aorta VSMC, calcitriol treatment induced uniform cellular growth patterns. Elastic fibers were more abundant in treated than • 
in control cultures [8]. 
In the CFK2 chondrogenic cell line, 1,25(OH)D directly stimulates transcription of mRNAs encoding VEGF-121 and VEGF-165 • 
isoforms. Enhanced VEGF expression also was evident in growth plate chondrocytes and osteoblasts in the tibia of juvenile mice 
treated systemically with 1,25(OH)D [9].
In rat aortic rings and A7r5 cells derived from fetal rat aortic smooth muscle, 22-oxa-1,25(OH)D induced prostacyclin synthesis but • 
did not cause any significant hypercalcemia [10].
HUVEC are demonstrated to be able to produce active vitamin D, and the endothelial 1-alpha hydroxilase activity is stimulated by • 
inflammatory cytokines. Exogenously added 1,25(OH)D or 25(OH)D significantly decreased HUVEC proliferation and increased 
the adhesion of monocytic U937 cells to HUVEC [11].
In primary cultures of ventricular myocytes isolated from neonatal rat hearts, treatment with 1,25(OH)D inhibited cell proliferation. • 
Proliferating cell nuclear antigen protein levels and protooncogene c-myc protein levels were specifically reduced by 1,25(OH)D. 
1,25(OH)D increased myocyte protein levels and increased cell size, suggesting that it induces cardiac myocyte hypertrophy [12]. 
Functional VDR, 1-alpha-hydroxylase and 24-hydroxylase are demonstrated in both the myocytes and fibroblasts of the heart, as • 
well as in the intact ventricular myocardium. VDR is shown to interact directly with the human B-type natriuretic peptide gene 
promoter, a surrogate marker of the transcriptional response to hypertrophy [13]. 
In HUVEC culture, the increase in protein levels of ICAM-1 and VCAM-1 induced by TNF-alpha was significantly decreased after • 
incubation of the cells with 1,25(OH)D [14].
1,25(OH)D induces a dose-dependent increase in VSMC proliferation in quiescent cells and in cells stimulated to grow. This effect • 
is mediated by an increase of the expression of VEGF [15].
Table 2: In vivo studies exploring the possible mechanisms of action of vitamin D in preventing cardiovascular disease
Possible mechanisms of action of vitamin D in preventing cardiovascular disease
In vitamin D receptor-null mice, renin expression and plasma angiotensin II production were increased several folds, leading to • 
hypertension, cardiac hypertrophy, and increased water intake. In wild-type mice, inhibition of 1,25(OH)D synthesis also led to an 
increase in renin expression, whereas 1,25(OH)D injection led to renin suppression [16].
In patients with a variety of kidney diseases, urinary MCP-1 protein and renal macrophage infiltration were each significantly but • 
inversely correlated with serum 1,2-OHD levels. Patients with acute renal inflammation had significantly lower levels of serum 
1,25(OH)D in comparison to patients with chronic ischemic disease despite similar levels of renal damage [17]. 
VSMC: vascular smooth muscle cell; 25(OH)D: 25 hydroxy vitamin D; 1,25(OH)D: 1,25 hydroxyvitamin D; HUVEC: umbilical vein cord endothelial 
cells; IL-6: interleukin 6; LPS: lipopolysaccharide; mRNA: messenger RNA; RAGE: receptor of advanced glycation end product; KFkB: nuclear factor 
kappa B; HMEC: microvessel endothelial cells; IL-8: interleukin 8; RANTES: regulated upon activation normal T cell exposed and secreted; PTHrP: 
parathyroid hormone-related peptide; IFN-gamma: gamma interferon; TfR: transferrin receptor; PI3 kinase: phosphatidylinositol 3-kinase; VEGF: 
vascular endothelial growth factor; VDR: vitamin D receptor; TNF-alpha: tumor necrosis factor alpha; ICAM-1: intercellular adhesion molecule-1; 
VCAM-1: vascular cell adhesion molecule-1; VEGF: vascular endothelial growth factor; MCP-1: monocyte chemoattractant protein-1
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Others: There are several heritable disorders that cause 
rickets in early infancy and childhood. Other acquired 
disorders of vitamin D deficiency include tumor-
induced osteomalacia, in which tumors secrete FGF-23. 
Hyperparathyroidism increases the metabolism of 25(OH)
D and 1,25(OH)D as well. Granulomatous disorders such 
as sarcoidosis, tuberculosis, and lymphomas produce 
a variety of enzymes that accelerate the conversion of 
25(OH)D to 1,25(OH)D.
Clinical syndromes associated with deficiency of 
25(OH)D
Table 4 summarizes the clinical associations of 25(OH)
D deficiencies.
Martin et al [27] studied the prevalence of cardiovascular 
risk factors and serum levels of 25(OH)D among 7186 
male and 7902 female adults from the third NHANES 
survey in the United States. The adjusted prevalence of 
hypertension (OR 1.30), DM (OR 1.98), obesity (OR 
2.29), and high serum triglyceride levels (OR 1.47) was 
significantly higher in the first than in the fourth quartile 
of serum 25(OH)D levels (P<.001 for all). Kim et al [28] 
studied the prevalence of hypovitaminosis D in adults 
with cardiovascular disease (CVD) using data from 
the NHANES survey between 2001 and 2004.  serum 
25(OH)D levels were divided into 3 categories (≥30, 20 
to 29, and <20 ng/ml). The burden of CVD increased with 
lower 25(OH)D categories, with 5.3%, 6.7%, and 7.3% 
CHD; 1.5%, 2.4%, and 3.2% heart failure; 2.5%, 2.0%, 
and 3.2% stroke; and 3.6%, 5.0%, and 7.7% peripheral 
arterial disease.  Hypovitaminosis D was more prevalent 
in those at high risk (OR 1.32), with CHD (OR 1.48), and 
both CHD and heart failure (OR 3.52) after controlling for 
age, race, and gender. They concluded that low 25(OH)D 
was highly prevalent in US adults with CVD, particularly 
those with both CHD and heart failure.
Wong et al [30] followed 1739 individuals without 
prior CVD for a mean of 5.4 years. Individuals with 
25(OH)D levels of less than 15 ng/ml at baseline had 
a multivariable-adjusted hazard ratio (HR) of 1.62 
(P=0.01) for incident cardiovascular events compared to 
those with levels above 15 ng/ml at baseline. This effect 
was evident in participants with hypertension (HR 2.13) 
but not in those without hypertension (HR 1.04). They 
concluded that 25(OH)D deficiency is associated with 
incident cardiovascular disease, and recommended the 
study of correction of vitamin D deficiency to prevent 
cardiovascular disease.
Dobnig et al [34] followed a cohort of 3258 patients 
scheduled for coronary angiography for a median of 7.7 
years. Multivariate-adjusted HR for patients in the lower 
two 25(OH)D quartiles were higher for all-cause mortality 
(2.08 and 1.53 respectively) and for cardiovascular 
mortality (2.22 and 1.82 respectively) compared with 
patients in the highest 25(OH)D quartile at baseline. 
Low 25(OH)D levels at baseline were significantly 
correlated with variables of inflammation (CRP and 
IL-6 levels), oxidative burden (serum phospholipid and 
glutathione levels), and cell adhesion (VCAM-1 and 
ICAM-1 levels). In a large cross sectional study, Pilz et 
al [35] evaluated 3299 Caucasian patients  referred for 
coronary angiography between 1997 and 2000. 25(OH)
D was negatively correlated with NT-proANP and was 
also adversely associated with higher NYHA classes 
and impaired left-ventricular function. After adjustment 
for cardiovascular risk factors, the HR of death due to 
heart failure and to sudden cardiac death were 2.84 and 
5.05 respectively when comparing patients with severe 
vitamin D deficiency with persons in the optimal range. 
Pilz et al [36] followed 3,316 patients who were referred 
for coronary angiography for a median duration of 7.75 
years. They found that low levels of 25(OH)D and 
1,25(OH)D at baseline were independently predictive for 
fatal strokes The odds ratio for fatal stroke were 0.58 per 
Z value of 25(OH)D and 0.62 per z value of 1,25(OH)D 
(P<0.001). 
Zittermann et al [37] evaluated 54 heart failure patients 
that had NYHA class 2 or more and 34 controls, and 
found in a nonlinear regression analysis that 25(OH)D 
and calcitriol were inversely correlated with NT-proANP, 
a predictor of CHF severity. They suggested that low 
25(OH)D may have contributed to the pathogenesis of 
congestive heart failure. Of note, there was no statistical 
difference in GFR between patients and controls. Boxer 
Table 3: Serum 25-hydroxyvitamin D concentrations and health status [18]
Health Status 25(OH)D level (ng/ml)
Vitamin D deficiency, leading to rickets in infants and children, and osteomalacia in adults < 10
Vitamin D levels are within normal range, but are likely to b inadequate for bone and overall health 10-20
Adequate for bone and overall health in normal individuals > 20
Potentially toxic, leading to hypercalcemia and hyperphosphatemia, although human data are limited Consistently >200
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Table 4: Clinical associations of 25(OH)D deficiencies 
Reported clinical associations of 25(OH)D deficiencies 
In community surveys, lower levels of 25(OH)D were associated with significantly higher adjusted prevalence of  hypertension, • 
DM, obesity and high serum triglyceride levels. They were also associated with an increased burden of CVD: CHD, heart failure, 
stroke, and peripheral arterial disease [27, 28].
In individuals without prior CVD, 25(OH)D deficiency at base line was an independent predictor of increasing apo A-I concentrations • 
and was associated with increased risk for future cardiovascular events [29, 30, 31].
In individuals with moderate risk for CHD, 1,25(OH)D levels were inversely correlated with the extent of vascular calcification. • 
Low levels of vitamin D  were independently associated with calcific aortic sclerosis in coronary artery disease patients [32, 33].
In patients referred for coronary angiography, low levels of  25(OH)D were significantly correlated with variables of inflammation, • 
oxidative burden, and cell adhesion. 25(OH)D level in these patients was negatively correlated with NT-proANP, NYHA classes 
and LVD. Low 25(OH)D levels were also independently predictive for fatal strokes, and associated with higher all-cause mortality 
and higher cardiovascular mortality [34, 35, 36].
In patients with severe CHF, 25(OH)D level was inversely correlated with NT-proANP levels. Low 25(OH)D level in those patients • 
were also associated with "urgent/high urgent" status on cardiac transplantation waiting list and associated with shorter 6-minute 
walk distance [37, 38, 39].
In patients presenting to hospital within 12 hours of the onset of MI symptoms and in patients admitted with first-ever stroke, low • 
levels of  25(OH)D were commoner than controls [40, 41]
In non-diabetic individuals, 25(OH)D levels were inversely associated with ISI and with plasma glucose concentration during the • 
oral-glucose-tolerance test at baseline. Low 25(OH)D levels were associated with higher 10-year risk of hyperglycemia, insulin 
resistance and metabolic syndrome [42, 43]. 
In diabetic patients, low 25(OH)D levels were commoner than controls, and were associated with higher values of HbA1c, triglyc-• 
erides, CRP and fibrinogen. Low 25(OH)D levels in diabetics were also associated with CVD [44]. 
In CKD patients, low 25(OH)D levels are  an independent predictor of death or ESRD [45].• 
Prolonged dietary deficiency of calcium and vitamin D was reported to cause extensive cardiac calcification in a child that substan-• 
tially reduced after adequate replacement of calcium and ergocalciferol [46].
Vitamin D deficiency was reported to cause heart failure in infants, which may improve with subsequent vitamin D and calcium • 
supplementation [47, 48].
CVD: cardiovascular disease; CHD: coronary heart disease; NT-proANP: N-terminal pro-atrial natriuretic peptide ; NYHA: New York Heart Association; 
LVD: left ventricular dysfunction; CHF: congestive heart failure; MI: myocardial infarction; ISI: Insulin Sensitivity Index; CKD: chronic kidney 
disease; ESRD: end stage renal disease
et al [39] studied the association between 25(OH)D level 
and the 6-minute walk distance and frailty level in 60 
patients with an ejection fraction of 40%. They found 
that longer 6-minute walk distance was correlated with 
higher 25(OH)D level, and that higher frailty score was 
significantly correlated with lower 25(OH)D levels. They 
suggested that 25(OH)D levels may contribute to lower 
aerobic capacity and frailty in patients with heart failure. 
Scraggy et al [40] evaluated 179 myocardial infarction 
(MI) patients presenting to hospital within 12 hours of 
the onset of symptoms. Mean 25(OH)D levels were 
significantly lower in MI patients than controls. The 
relative risk of MI for subjects with 25(OH)D levels equal 
to or above the median was 0.43 compared to subjects 
below the median. 
In another study, Cigolini et al [44] studied 459 consecutive 
type 2 diabetic patients and a control group of 459 age- and 
sex-matched non-diabetic volunteers. In fully adjusted 
logistic regression models, low 25(OH)D level (< 20 ng/
ml) was commoner in diabetic patients than in control 
subjects (60.8% versus 42.8%, p < 0.001).  In addition, 
diabetic patients with low 25(OH)D had increased 
prevalence of higher values of HbA1c, triglycerides, CRP, 
and fibrinogen levels. There was an association between 
low 25(OH)D and prevalence of CVD (OR 1.7, p < 0.01) 
that remained statistically significant after adjustment for 
classical risk factors. They concluded the existence of a 
high prevalence of low 25(OH)D in diabetic patients and 
a strong association between 25(OH)D concentration and 
prevalence of CVD.
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In an interesting study by Ravani et al [45], they enrolled 
168 consecutive new referrals to a CKD clinic over a 2 
year period and followed them for up to 6 years. 25(OH)D 
level was as an independent predictor of study outcomes, 
death or end-stage renal disease (ESRD), when adjusted 
for age, heart failure, smoking, CRP, albumin, phosphate, 
use of angiotensin converting enzyme inhibitors (ACEi) 
or angiotensin receptor blockers (ARBs), and estimated 
GFR. 
Zaidi et al [46] reported the case of a 6-year-old girl 
who presented with extensive cardiac calcifications 
due to secondary hyperparathyroidism resulting from 
prolonged dietary deficiency of calcium and vitamin 
D. Cardiac calcifications substantially reduced after 
treatment with adequate daily replacement of calcium and 
ergocalciferol. Also, Kosecik et al [48] described a case 
of dilated cardiomyopathy due to nutritional vitamin D 
deficiency rickets that improved with subsequent vitamin 
D and calcium supplementation.
Human studies on the effects of vitamin D supplemen-
tation on health
Table 5 presents the protocols and results that evaluated 
the effect of vitamin D supplementation. In a unique 
randomized clinical trial, Schleithoff et al [49] evaluated 
the effect of 25(OH)D supplementation on the survival 
rate and different biochemical variables in patients with 
CHF. Patients were randomized to receive either 50 mcg 
of 25(OH)D plus 500 mg calcium supplement or placebo 
plus 500 mg calcium supplement for 9 months. The 
pro-inflammatory cytokine tumor necrosis factor alpha 
(TNF-alpha) increased in the control group but remained 
constant in the treatment group. They concluded that 
25(OH)D therapy reduces the inflammatory milieu in 
congestive heart failure patients and might serve as a 
new anti-inflammatory agent for the future treatment of 
the disease. The survival rate did not differ significantly 
between the study groups during the follow-up period.
Low 25(OH)D levels are common in CKD pre-dialysis 
patient [21]. Several data suggested that urinary protein 
losses may be more important than loss of GFR in inducing 
25(OH)D depletion. In fact, consistent with recent 
analyses using NHANES 3 data, the graded relationship 
between serum 25(OH)D levels and proteinuria was 
present even at sub-nephrotic levels. The K-DOQI [59] 
work group extrapolated from epidemiological data to 
make opinion-based recommendations to maintain serum 
25(OH)D levels above 30 ng/ml in patients with CKD 
stage 3 or 4. There have been no randomized controlled 
trials to study the magnitude of benefit of 25(OH)D 
supplementation on lowering serum PTH levels.
Naves-Díaz et al [54] studied the survival benefit of oral 
active vitamin D in HD patients from six Latin American 
countries (FME Register as part of the CORES study) 
followed for a median of 16 months. After adjustment for 
potential confounders, the 7,203 patients who received 
oral active vitamin D had significant reductions in overall, 
cardiovascular, infectious and neoplastic mortality 
compared to the 8,801 patients that had not received 
vitamin D. The survival benefit of oral active vitamin 
D was seen in those patients receiving mean daily doses 
of less than 1 mcg with the highest reduction associated 
with the lowest dose.
Kovesdy et al [56] studied a historical cohort of incident 
HD patients who lived throughout the United States 
between January 1996 and December 1999. During this 
period, 37,173 HD patients received activated injectable 
vitamin D and 13,864 did not. At 2 years, mortality 
rates were 13.8/100 person-years in the group that 
received injectable vitamin D compared with 28.6/100 
person-years in the group that did not (P < 0.001). After 
adjustment for several potential confounders, the 2-year 
survival advantage associated with the group that did 
receive injectable vitamin D was 20%. The incidence 
of cardiovascular-related mortality was 7.6/100 person-
years in the injectable vitamin D group, compared with 
14.6/100 person-years in the non-vitamin D group 
(P<0.001).
A recent clinical trial by Lappe et al [58] was designed to 
determine the efficacy of calcium alone and calcium plus 
vitamin D in reducing incident cancer risk in community-
dwelling women randomly selected from the population 
of healthy postmenopausal women. Cancer incidence 
was significantly lower in the calcium plus vitamin D 
women than in the placebo control subjects. In multiple 
logistic regression models, both treatment and serum 
25-hydroxyvitamin D concentrations were significant, 
independent predictors of cancer risk. 
Significant gaps in knowledge 
The optimum window of serum 25(OH)D level is yet 
to be determined, benefits and risks of large doses of 
supplementation of vitamin D need to be assessed, and 
large randomized clinical testing with sufficiently high 
doses of vitamin D for CVD prevention do not exist.
Knowledge of the desirable concentration of vitamin D 
is important, since low levels are associated with disease 
states and higher levels are associated with hypercalcemia. 
In fact, there is hesitation to administer large doses of 
vitamin D supplementation for fear of hypercalcemia 
and hyperphosphatemia, because these disorders can 
affect patient function as well as patient survival.  On 
the other hand, high 25(OH)D concentration may in fact 
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Table 5: Human studies on the effects of vitamin D supplementation on health in general and CVD in particular
Study  
population
Author Type of Study Outcome
Heart failure 
patients




One hundred twenty-three CHF patients randomly received either 50 mcg 
vitamin D or placebo for 9 months. Compared with baseline, PTH was signif-
icantly lower and the anti-inflammatory cytokine interleukin 10 was signifi-
cantly higher in the vitamin D group after 9 months. The survival rate did not 
differ significantly between the study groups during the follow-up period.
Hypertensive 
patients
Jespersen et al [50] Controlled 
clinical trial
The rapid effects of 1,25(OH)D were assessed over 120 min after a bolus 
injection in eight men with essential hypertension and in nine healthy men, 
and a placebo group of 10 healthy men was also included. In the hyperten-
sive patients, a transient increase in blood pressure and a reciprocal fall in 
cardiac output were observed after 1,25(OH)D injection.
Diabetic 
patients




A single dose of 100,000 IU vitamin D2 or placebo was administered to 
34 patients with type 2 diabetes with 25(OH)D levels < 20 ng/ml. Vitamin 
D supplementation significantly improved flow mediated vasodilatation 
(FMD) of the brachial artery by 2.3% and significantly decreased systolic 
blood pressure by 14 mmHg compared with placebo.
Tarcin et al [52] Prospective  
cohort
Twenty-three asymptomatic vitamin D-deficient subjects received 300,000 
IU IM monthly for 3 months. Brachial artery flow mediated dilatation 
(FMD) measurements were significantly lower in 25(OH)D deficient 
subjects than controls (P = 0.001) and improved after replacement therapy 
(P = 0.002). Post-treatment values of lipid peroxidation as measures of 
thiobarbituric acid reactive substances (TBARS) were significantly lower 
than pre-treatment levels (P < 0.001). A positive correlation between FMD 
and 25(OH)D (r = 0.45; P = 0.001) was observed. There was a significant 
increase in leptin levels after therapy, and the leptin levels were positively 








Patients in CKD stage 3 and 4 with secondary hyperparathyroidism 
(SHPT) were randomized to oral paricalcitol (N=107) or placebo (N= 13) 
and followed for up to 24 weeks. At the final visit 51% of the paricalcitol 
patients compared to 25% placebo patients had reduction in proteinuria 
(P= 0.004). Reduction of proteinuria favored patients on paricalcitol, re-
gardless of age, sex, race, diabetes mellitus, hypertension, or use of thera-
pies to block the renin-angiotensin-aldosterone system (RAAS).
Naves-Díaz et al [54] Prospective  
cohort
Among HD patients prospectively followed up for a median of 16 months, 
7203 HD patients who received oral active vitamin D had significant 
reductions in overall, cardiovascular, infectious and neoplastic mortal-
ity compared to 8801 HD patients that had not received vitamin D. The 
survival benefit of oral active vitamin D was seen in those patients receiv-
ing mean daily doses of less than 1 mcg with the highest reduction associ-
ated with the lowest dose. 
Shoji et al [55] Prospective  
cohort
Among a cohort of ESRD patients undergoing HD, multivariate analysis 
showed that cardiovascular mortality was significantly reduced with treat-
ment with alfacalcidol (HR 0.377, P = 0.022).
Teng et al [56] Historical  
cohort
In a historical cohort of HD patients who lived throughout the United States 
between January 1996 and December 1999, active injections of vitamin D 
were given to 37173 patients and 13864 did not receive the drug. The 
2-year survival advantage associated with injectable vitamin D was 20%, 
and cardiovascular-related mortality was 7.6/100 person-years compared 
to 14.6/100 person-years in the non-vitamin D group (P < 0.001).
Kovesdy et al [57] Historical  
cohort
Among 520 male CKD patients in stages 3-5, there were 258 subjects 
who received treatment with calcitriol for a median duration of 2.1 years. 
The incidence rate ratios for mortality and combined death and dialysis 
initiation were significantly lower in treated versus untreated patients (P 
< .001).




Community-dwelling healthy postmenopausal women were randomly 
assigned to receive supplemental calcium alone, supplemental calcium 
plus vitamin D3 or placebo (N=1179). In multiple logistic regression 
models, both treatment and serum 25(OH)D concentrations were signifi-
cant, independent predictors of cancer risk.
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suppress PTH levels, which is important in the renal 
patient.  Therefore, knowledge of the desirable window 
for vitamin D level is necessary. Factors that determine 
this desirable level include the best level to achieve its 
skeletal and non-skeletal functions. Parenthetically 
published levels necessary for healthy skeleton seem 
similar to levels thought necessary to optimize 25(OH)
D’s cardiovascular protective effects.  As such, we 
believe that there is in fact a wide window of opportunity 
to achieve this desirable level (30-70 ng/ml) for health. 
The relationship between 25(OH)D supplement and its 
levels has been well documented. For each 1000 IU dose 
of vitamin D, an expected increase of 10 ng/ml in 25(OH)
D level is expected.  It should be noted, further, that 
supplements of up to 5000 IU daily are highly unlikely to 
lead to 1,25(OH)D toxicity.
What remains is to perform a critical double-blinded 
controlled trial to investigate whether oral 25(OH)D 
supplementation, to reach the target window, is able to 
prevent cardiovascular risk factors and CVD mortality, 
particularly in those with early CKD, hypertension, DM 
and those with the metabolic syndrome.
Conclusions
This review evaluated the current literature on vitamin 
D deficiency  and its association with multiple disease 
processes, particularly cardiovascular disease. There is 
emerging evidence to suggest a need for a randomized 
prospective study to determine the beneficial effect of 
Vitamin D therapy above and beyond the knowledge of 
strong association between health and vitamin D level.
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